Grand Pharmaceutical Group Limited (00512.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	24.3B	12.3B	11.6B	10.5B	9.6B
Cost of Revenue	11.0B	5.5B	4.9B	4.0B	3.6B
Gross Profit	13.3B	6.8B	6.7B	6.5B	6.0B
Operating Expenses
R&D Expense	1.1B	502.9M	588.1M	572.0M	531.9M
SG&A Expense	9.6B	5.2B	4.6B	3.3B	3.4B
General & Admin Expense	2.8B	1.4B	1.4B	1.2B	1.1B
Selling & Marketing Expense	7.0B	3.8B	3.3B	2.6B	2.3B
Other Expenses	(280.2M)	39.0M	(644.1M)	—	(494.6M)
Total Operating Expenses	10.3B	5.7B	4.6B	3.9B	3.4B
Cost and Expenses	21.4B	11.2B	9.5B	7.9B	7.0B
Operating Income (EBIT)	2.9B	1.0B	2.2B	2.7B	2.5B
Non-Operating
Interest Income	—	7.4M	6.3M	7.7M	19.8M
Interest Expense	333.2M	162.3M	180.2M	205.1M	137.5M
Net Interest Income	(333.2M)	(155.0M)	(173.9M)	(197.4M)	(117.7M)
Other Non-Op Income/Expense	870.0M	451.6M	680.3M	(319.2M)	(731.0K)
Non-Operating Income (excl Interest)	(1.1B)	(724.4M)	(860.6M)	89.0M	(180.5M)
EBT (Pre-Tax Income)	3.8B	1.5B	2.9B	2.3B	2.5B
Income Tax Expense	581.4M	249.8M	386.3M	448.8M	418.6M
Bottom Line
Net Income	3.2B	1.2B	2.5B	1.9B	2.1B
Earnings from Cont. Ops	3.2B	1.2B	2.5B	1.9B	2.1B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	3.2B	1.2B	2.5B	1.9B	2.1B
Per Share
Basic EPS	HK$0.91	HK$0.35	HK$0.70	HK$0.54	HK$0.59
Diluted EPS	HK$0.91	HK$0.35	HK$0.70	HK$0.54	HK$0.59
Revenue Per Share	HK$6.93	HK$3.51	HK$3.33	HK$3.00	HK$2.70
Shares
Basic Shares Outstanding	3.5B	3.5B	3.5B	3.5B	3.5B
Diluted Shares Outstanding	3.5B	3.5B	3.5B	3.5B	3.5B
Profitability Metrics
EBITDA	5.1B	2.3B	3.4B	3.0B	3.1B
D&A	1.1B	542.8M	503.7M	392.2M	394.9M
EBIT	4.0B	1.8B	2.9B	2.6B	2.7B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026